Randomized phase III trial to compare radiation therapy alone with radiation therapy and concomitant anti-EGFr antibody (C225) for locally advanced squamous cell carcinomas of the head and neck

Trial Profile

Randomized phase III trial to compare radiation therapy alone with radiation therapy and concomitant anti-EGFr antibody (C225) for locally advanced squamous cell carcinomas of the head and neck

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2015 Retrospective results published in the Journal of Clinical Oncology.
    • 01 Jan 2010 Five-year survival data published in Lancet Oncology.
    • 23 Sep 2008 Updated 5-year overall survival data have been presented at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Boston.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top